Validation of an LC-MS/MS Method to Quantify the New TRPC6 Inhibitor SH045 (Larixyl N -methylcarbamate) and Its Application in an Exploratory Pharmacokinetic Study in Mice

• Published in: Pharmaceuticals (Basel, Switzerland) Switzerland), 2021-03, Vol.14 (3), p.259
• Main Authors: Chai, Xiao-Ning, Ludwig, Friedrich-Alexander, Müglitz, Anne, Schaefer, Michael, Yin, Hai-Yan, Brust, Peter, Regenthal, Ralf, Krügel, Ute
• Format: Article
• Language: English
• Subjects: channelopathies; Chromatography; Edema; Kidney diseases; labdane; larixol; LC-MS/MS; mice; Oils & fats; Optimization; Pharmacokinetics; Plasma
• ISSN: 1424-8247; 1424-8247
• DOI: 10.3390/ph14030259

TRPC6 (transient receptor potential cation channels; canonical subfamily C, member 6) is widespread localized in mammalian tissues like kidney and lung and associated with progressive proteinuria and pathophysiological pulmonary alterations, e.g., reperfusion edema or lung fibrosis. However, the understanding of TRPC6 channelopathies is still at the beginning stages. Recently, by chemical diversification of (+)-larixol originating from resin traditionally used for inhalation, its methylcarbamate congener, named SH045, was obtained and identified in functional assays as a highly potent, subtype-selective inhibitor of TRPC6. To pave the way for use of SH045 in animal disease models, this study aimed at developing a capable bioanalytical method and to provide exploratory pharmacokinetic data for this promising derivative. According to international guidelines, a robust and selective LC-MS/MS method based on MRM detection in positive ion mode was established and validated for quantification of SH045 in mice plasma, whereby linearity and accuracy were demonstrated for the range of 2-1600 ng/mL. Applying this method, the plasma concentration time course of SH045 following single intraperitoneal administration (20 mg/kg body weight) revealed a short half-life of 1.3 h. However, the pharmacological profile of SH045 is promising, as five hours after administration, plasma levels still remained sufficiently higher than published low nanomolar IC values. Summarizing, the LC-MS/MS method and exploratory pharmacokinetic data provide essential prerequisites for experimental pharmacological TRPC6 modulation and translational treatment of TRPC6 channelopathies.